Details of the Drug

General Information of Drug (ID: DMTY6OF)

Drug Name
ATI-501
Indication
Disease Entry ICD 11 Status REF
Alopecia ED70 Phase 2 [1]
Drug Type
Small molecular drug
Cross-matching ID
PubChem CID
23585272
TTD ID
D6INZ9

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [2]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alopecia
ICD Disease Classification ED70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Janus kinase 1 (JAK-1) DTT JAK1 6.35E-07 -0.28 -1.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03594227) ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Aclaris Therapeutics.